QQQ   352.50 (+1.05%)
AAPL   179.14 (+0.74%)
MSFT   326.17 (+0.86%)
META   266.69 (+1.17%)
GOOGL   122.76 (+0.21%)
AMZN   125.15 (+3.23%)
TSLA   232.33 (+3.46%)
NVDA   384.53 (+2.61%)
NIO   7.68 (-1.03%)
BABA   86.89 (+1.89%)
AMD   121.25 (+2.90%)
T   15.93 (-1.06%)
F   13.50 (-0.66%)
MU   65.10 (-2.92%)
CGC   0.70 (-2.56%)
GE   106.95 (+0.82%)
DIS   92.04 (-0.52%)
AMC   4.60 (-2.75%)
PFE   39.03 (+0.36%)
PYPL   64.49 (+0.70%)
NFLX   405.54 (+1.44%)
QQQ   352.50 (+1.05%)
AAPL   179.14 (+0.74%)
MSFT   326.17 (+0.86%)
META   266.69 (+1.17%)
GOOGL   122.76 (+0.21%)
AMZN   125.15 (+3.23%)
TSLA   232.33 (+3.46%)
NVDA   384.53 (+2.61%)
NIO   7.68 (-1.03%)
BABA   86.89 (+1.89%)
AMD   121.25 (+2.90%)
T   15.93 (-1.06%)
F   13.50 (-0.66%)
MU   65.10 (-2.92%)
CGC   0.70 (-2.56%)
GE   106.95 (+0.82%)
DIS   92.04 (-0.52%)
AMC   4.60 (-2.75%)
PFE   39.03 (+0.36%)
PYPL   64.49 (+0.70%)
NFLX   405.54 (+1.44%)
QQQ   352.50 (+1.05%)
AAPL   179.14 (+0.74%)
MSFT   326.17 (+0.86%)
META   266.69 (+1.17%)
GOOGL   122.76 (+0.21%)
AMZN   125.15 (+3.23%)
TSLA   232.33 (+3.46%)
NVDA   384.53 (+2.61%)
NIO   7.68 (-1.03%)
BABA   86.89 (+1.89%)
AMD   121.25 (+2.90%)
T   15.93 (-1.06%)
F   13.50 (-0.66%)
MU   65.10 (-2.92%)
CGC   0.70 (-2.56%)
GE   106.95 (+0.82%)
DIS   92.04 (-0.52%)
AMC   4.60 (-2.75%)
PFE   39.03 (+0.36%)
PYPL   64.49 (+0.70%)
NFLX   405.54 (+1.44%)
QQQ   352.50 (+1.05%)
AAPL   179.14 (+0.74%)
MSFT   326.17 (+0.86%)
META   266.69 (+1.17%)
GOOGL   122.76 (+0.21%)
AMZN   125.15 (+3.23%)
TSLA   232.33 (+3.46%)
NVDA   384.53 (+2.61%)
NIO   7.68 (-1.03%)
BABA   86.89 (+1.89%)
AMD   121.25 (+2.90%)
T   15.93 (-1.06%)
F   13.50 (-0.66%)
MU   65.10 (-2.92%)
CGC   0.70 (-2.56%)
GE   106.95 (+0.82%)
DIS   92.04 (-0.52%)
AMC   4.60 (-2.75%)
PFE   39.03 (+0.36%)
PYPL   64.49 (+0.70%)
NFLX   405.54 (+1.44%)

Pliant Therapeutics (PLRX) Stock Forecast, Price & News

$22.88
-0.21 (-0.91%)
(As of 11:21 AM ET)
Compare
Today's Range
$22.66
$23.24
50-Day Range
$20.99
$30.56
52-Week Range
$6.37
$36.64
Volume
50,822 shs
Average Volume
809,388 shs
Market Capitalization
$1.35 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.83

Pliant Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
107.2% Upside
$47.83 Price Target
Short Interest
Bearish
10.41% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
1.20mentions of Pliant Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.71 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.99) to ($3.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

172nd out of 981 stocks

Pharmaceutical Preparations Industry

75th out of 484 stocks


PLRX stock logo

About Pliant Therapeutics (NASDAQ:PLRX) Stock

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

PLRX Stock News Headlines

Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Pliant Therapeutics (NASDAQ:PLRX) Shares Gap Up to $21.53
BTIG Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)
See More Headlines

PLRX Price History

PLRX Company Calendar

Last Earnings
5/09/2023
Today
6/08/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PLRX
Fax
N/A
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$47.83
High Stock Price Forecast
$63.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+107.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
11 Analysts

Profitability

Net Income
$-123,320,000.00
Net Margins
-1,359.22%
Pretax Margin
-1,359.22%

Debt

Sales & Book Value

Annual Sales
$9.69 million
Book Value
$6.43 per share

Miscellaneous

Free Float
55,843,000
Market Cap
$1.37 billion
Optionable
Not Optionable
Beta
1.40

Key Executives

  • Dr. Bernard Coulie M.B.A. (Age 56)
    M.D., MBA, Ph.D., Pres, CEO & Director
    Comp: $889.01k
  • Dr. Keith Lamont Cummings M.B.A. (Age 45)
    M.D., Chief Financial Officer
    Comp: $606.12k
  • Mr. Mike Ouimette (Age 49)
    Gen. Counsel & Corp. Sec.
    Comp: $537.99k
  • Mr. Johannes P. Hull (Age 47)
    Chief Bus. Officer
    Comp: $582.49k
  • Dr. Éric Lefebvre M.D. (Age 58)
    Chief Medical Officer
    Comp: $713.81k
  • Dr. Rik Derynck
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Dean Sheppard M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Bill DeGrado Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Hal Chapman M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Craig D. Muir
    Interim Chief Technology Officer













PLRX Stock - Frequently Asked Questions

Should I buy or sell Pliant Therapeutics stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PLRX shares.
View PLRX analyst ratings
or view top-rated stocks.

What is Pliant Therapeutics' stock price forecast for 2023?

11 brokers have issued 1-year price objectives for Pliant Therapeutics' shares. Their PLRX share price forecasts range from $33.00 to $63.00. On average, they predict the company's share price to reach $47.83 in the next twelve months. This suggests a possible upside of 107.2% from the stock's current price.
View analysts price targets for PLRX
or view top-rated stocks among Wall Street analysts.

How have PLRX shares performed in 2023?

Pliant Therapeutics' stock was trading at $19.33 at the beginning of the year. Since then, PLRX stock has increased by 19.5% and is now trading at $23.09.
View the best growth stocks for 2023 here
.

Are investors shorting Pliant Therapeutics?

Pliant Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 6,160,000 shares, an increase of 48.4% from the April 30th total of 4,150,000 shares. Based on an average daily volume of 708,200 shares, the short-interest ratio is presently 8.7 days.
View Pliant Therapeutics' Short Interest
.

When is Pliant Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our PLRX earnings forecast
.

How were Pliant Therapeutics' earnings last quarter?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by $0.01. The business earned $1.33 million during the quarter, compared to analyst estimates of $1.96 million. Pliant Therapeutics had a negative trailing twelve-month return on equity of 39.05% and a negative net margin of 1,359.22%.

What other stocks do shareholders of Pliant Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), Ampio Pharmaceuticals (AMPE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

When did Pliant Therapeutics IPO?

(PLRX) raised $90 million in an initial public offering (IPO) on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager.

What is Pliant Therapeutics' stock symbol?

Pliant Therapeutics trades on the NASDAQ under the ticker symbol "PLRX."

Who are Pliant Therapeutics' major shareholders?

Pliant Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (7.66%), CHI Advisors LLC (5.07%), Price T Rowe Associates Inc. MD (3.56%), BlackRock Inc. (3.09%), First Light Asset Management LLC (2.41%) and Jennison Associates LLC (2.08%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Keith Lamont Cummings, Matthew Dunnigan and Mike Ouimette.
View institutional ownership trends
.

How do I buy shares of Pliant Therapeutics?

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pliant Therapeutics' stock price today?

One share of PLRX stock can currently be purchased for approximately $23.09.

How much money does Pliant Therapeutics make?

Pliant Therapeutics (NASDAQ:PLRX) has a market capitalization of $1.37 billion and generates $9.69 million in revenue each year. The company earns $-123,320,000.00 in net income (profit) each year or ($2.86) on an earnings per share basis.

How can I contact Pliant Therapeutics?

Pliant Therapeutics' mailing address is 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is pliantrx.com. The company can be reached via phone at 650-481-6770 or via email at ir@pliantrx.com.

This page (NASDAQ:PLRX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -